- Home
- CPRX vs CRNX Comparison
CPRX vs CRNX Comparison
Compare CPRX & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- CRNX
- Stock Information
- Founded
- CPRX 2002
- CRNX 2008
- Country
- CPRX United States
- CRNX United States
- Employees
- CPRX N/A
- CRNX N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- CPRX Health Care
- CRNX Health Care
- Exchange
- CPRX Nasdaq
- CRNX Nasdaq
- Market Cap
- CPRX 2.6B
- CRNX 2.8B
- IPO Year
- CPRX 2006
- CRNX 2018
- Fundamental
- Price
- CPRX $20.02
- CRNX $34.20
- Analyst Decision
- CPRX Strong Buy
- CRNX Strong Buy
- Analyst Count
- CPRX 5
- CRNX 7
- Target Price
- CPRX $33.20
- CRNX $74.33
- AVG Volume (30 Days)
- CPRX 1.5M
- CRNX 1.1M
- Earning Date
- CPRX 11-05-2025
- CRNX 11-11-2025
- Dividend Yield
- CPRX N/A
- CRNX N/A
- EPS Growth
- CPRX 183.96
- CRNX N/A
- EPS
- CPRX 1.65
- CRNX N/A
- Revenue
- CPRX $558,499,000.00
- CRNX $1,392,000.00
- Revenue This Year
- CPRX $16.51
- CRNX $489.51
- Revenue Next Year
- CPRX $9.58
- CRNX $661.93
- P/E Ratio
- CPRX $12.10
- CRNX N/A
- Revenue Growth
- CPRX 28.55
- CRNX 0.51
- 52 Week Low
- CPRX $19.15
- CRNX $24.10
- 52 Week High
- CPRX $26.58
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- CPRX 46.35
- CRNX 58.12
- Support Level
- CPRX $19.66
- CRNX $33.42
- Resistance Level
- CPRX $20.52
- CRNX $37.23
- Average True Range (ATR)
- CPRX 0.67
- CRNX 1.48
- MACD
- CPRX 0.03
- CRNX -0.01
- Stochastic Oscillator
- CPRX 42.08
- CRNX 56.59
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.